134.430 -

-1.790 (-1.31%)
Range 133.545 - 137.200   (2.74%)
Open 135.125
Previous Close 136.220
Bid Price -
Bid Volume -
Ask Price -
Ask Volume -
Volume 17,510,274
Value 2,988,118,027
Remark -
Delayed prices. Updated at 30 May 2026 08:15.
Data powered by
View All Events

About Gilead Sciences

Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead�s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company�s products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.

There are 30 followers

Followers
0
Followers
0
Followers
5
Followers
0
wkp
Followers
0
CXM
Followers
3
Followers
0
Followers
2
Followers
0
Followers
0
spy
Followers
0
Followers
0
Followers
2
Followers
0
Followers
21
Followers
0
Followers
0
Followers
1
Followers
0
Followers
3
Followers
13
Followers
0
Followers
0
advanced
Followers
0
Followers
0
Followers
0
Followers
1
Followers
0
Followers
42
Followers
0